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Abstract 
Background: A number of metabolic abnormalities, such as dysglycaemia, insulin resistance, lipodystrophy and 
dyslipidaemia, are associated with the use of antiretroviral drugs. We aimed to assess the effects of long-term antiret-
roviral exposure on blood pressure, glycaemia, insulin secretion and anthropometric measures in black South African 
women.
Methods: A convenience sample of HIV-infected women on first-line ART for a median of 16 months at baseline, 
had the following evaluations twice, at baseline and after approximately 5 years: anthropometry, including skin fold 
thicknesses, blood pressure, oral glucose test, and insulin. Insulin sensitivity and secretion (HOMA-IR, IGI and DIo) were 
estimated.
Results: At baseline more than half the 103 women were using stavudine and efavirenz. The median interval 
between baseline and follow-up evaluation was 66 months. Weight, waist circumference, and waist-hip ratio 
increased over time, while limb skinfold thickness decreased over time. Systolic and diastolic blood pressure increased 
significantly and the proportion of participants with hypertension increased from 3.9 to 15.5% (p < 0.001). There were 
increases from baseline in plasma glucose concentrations at 30 and 120 min; insulin concentrations at 0 and 30 min; 
and IGI and DIo. The proportion of participants with diabetes increased from 1 to 7.5% (p = 0.070).
Conclusion: In black South African women with long-term exposure to ART, increases in hypertension and possibly 
diabetes were observed. Participants experienced an increase in central fat and a decrease in peripheral fat distribu-
tion. Early identification and management of these metabolic changes are important, especially in a region with the 
highest HIV-infected population in the world.
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Background
Africa has made great strides in expanding access to 
antiretroviral therapy (ART), with an estimated 7.6 mil-
lion people in sub-Saharan Africa receiving treatment 
by December 2012 [1]. The increase in access to ART 
has resulted in a dramatic decline in HIV-related deaths. 
However, several antiretroviral drugs are associated with 
a number of metabolic abnormalities [2] including dys-
lipidaemia, lipodystrophy, insulin resistance and dysgly-
cemia [3].
Several studies from Africa have shown an increased 
prevalence of dysglycaemia in HIV-infected patients, 
especially in patients on ART, but the duration of ART 
exposure was generally under 3  years [4–6]. There are 
conflicting data with regard to the impact of HIV and 
ART on hypertension, with some studies showing an 
increased risk of hypertension [7, 8] and others showing 
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no association [9–11]. A recent systematic review [12] 
found that HIV-infected patients in sub-Saharan Africa, 
irrespective of ART status, had lower systolic and dias-
tolic blood pressure (BP) than HIV-uninfected controls.
ART-related lipoatrophy is common in low-and-mid-
dle income countries (LMICs) [13–15], where stavudine 
has only recently been phased out and zidovudine is still 
widely being used. Anthropometric studies show that fat 
loss is best detected by triceps skinfold and hip circum-
ference measurements [13, 16]. Central fat accumulation 
on ART is thought to be a consequence of treating the 
HIV infection, as the gain in trunk and visceral fat is no 
different between HIV-infected participants on ART and 
HIV-uninfected controls, and does not differ by antiret-
roviral class [17].
Little is known about the long-term metabolic effects 
of ART in LMICs. We aimed to assess the effects of long-
term ART exposure on blood pressure, glycaemia, insulin 
secretion and anthropometric measures in black South 
African women.
Results
Participant characteristics are presented in Table  1. We 
enrolled 103 of the 345 women assessed at baseline for 
follow-up assessment. At baseline the participants had 
spent a median of 16  months on first-line ART and 
almost all were using stavudine (91%) and lamivudine 
(100%). At follow-up 84% were still on first-line ART but 
the percentage of those using stavudine had decreased 
to 39%, and those using zidovudine had increased from 
10 to 38%. The median time on ART at follow-up was 
82 months (6.8 years).
As shown in Table  2, waist circumferences increased 
significantly (p = 0.038), while hip and mid-thigh circum-
ferences decreased (p  <  0.001). All skinfold thicknesses 
changed significantly from baseline to follow-up. All 
25% of the participants who reported having lipoatrophy 
at baseline, reported none at follow-up. However, when 
using objective measures [13] based on thigh and triceps 
cut points, the percentage of participants with lipoat-
rophy increased from 44 to 64%; p = 0.010. At baseline, 
60% of those who self-reported moderate or severe fat 
loss in 2 or more regions, were correctly classified using 
thigh and tricep skinfold cut points, while 61.5% of those 
who reported having lost none, or minimal amounts of 
fat were correctly classified (p = 0.002).
Both systolic and diastolic blood pressures increased 
(p < 0.001) from baseline to follow-up (Table 3). Plasma 
glucose concentrations at 30 and 120  min, and insulin 
concentrations at 0 and 30  min also increased signifi-
cantly from baseline to follow-up (p  <  0.050). Although 
the homeostatic assessment model (HOMA-IR) tended 
to increase (p = 0.089) from baseline to follow-up, both 
the insulinogenic index (IGI) and the oral disposition 
index (DIo) increased significantly (p < 0.001).
The proportion of participants with hypertension 
increased from baseline to follow-up, from 3.9 to 15.5%; 
p  <  0.001 (Table  4). While the proportion of partici-
pants with impaired glucose tolerance (IGT), impaired 
fasting glucose (IFG) and dysglycemia did not change 
Table 1 Comparison of baseline and follow-up characteristics of female participants
Baseline median (IQR), n = 84 Follow-up median (IQR), n = 77
Age 33.5 (30.0–40.0) 40.1 (35.7–45.4)
Current CD4 count 372 (261–471) 564 (427–774)
Time on ART (months) 16.0 (10.0–26.0) 82.4 (73.8–94.1)
n (%) n (%)
No schooling 5 (4.8)
Primary School 14 (13.6)
Secondary School 83 (80.6)
Tertiary 1 (1.0)
1st line ART 84 (100) 65 (84.4)
2nd line ART 0 (0) 12 (15.6)
Stavudine 76 (90.5) 30 (39.0)
Lamivudine 84 (100) 77 (100)
Zidovudine 8 (9.5) 29 (37.7)
Tenofovir 0 (0.0) 18 (23.4)
Lopinavir 0 (0.0) 12 (15.6)
Efavirenz 41 (48.8) 36 (46.8)
Nevirapine 43 (51.2) 29 (37.7)
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significantly from baseline to follow-up, there was a trend 
to an increase in the proportion of participants with dia-
betes (1% to 7.5%; p = 0.070). At baseline and follow-up, 
diabetes, hypertension and dysglycaemia were signifi-
cantly associated with lipoatrophy (p  <  0.001) based on 
thigh and tricep skinfold cut points.
Stavudine, efavirenz and nevirapine were significantly 
associated with diabetes, hypertension and dysglycae-
mia at follow-up (Table 5). Lipoatrophy was significantly 
associated (p < 0.001) with zidovudine, tenofovir, lopina-
vir in addition to stavudine, efavirenz and nevirapine.
Discussion
Our results show that long term exposure to ART in 
South African women is associated with increases in 
blood pressure, glucose and insulin levels. These women 
also experienced changes in body composition with a sig-
nificant increase in the waist-hip ratio, and in the prev-
alence of lipoatrophy when objective anthropometric 
measures (thigh and triceps skinfold cut points [13]) were 
used instead of the subjective measure of patient report. 
These metabolic and body composition changes are all 
associated with an increased cardiovascular risk [18].
The prevalence of hypertension at baseline in our 
study was threefold lower than in women of a similar 
age-group from a similar area in Cape Town who par-
ticipated in a community-based cardiovascular risk 
factor study (CRIBSA). At follow-up the prevalence of 
hypertension was lower when compared to similarly 
aged women from the CRIBSA Study. Although HIV 
testing was not performed in the CRIBSA Study, par-
ticipants were not known to be on ART and based on 
local data, the HIV-infected proportion was estimated 
to be about 10% [19]. Another study from rural Kwa-
Zulu Natal, South Africa [20] reported a 20% prevalence 
of hypertension in HIV-infected women compared to 
40% in HIV-uninfected women 15 years and older. The 
lower BMI in people on ART compared to the HIV 
negative participants may be an explanation for the 
lower prevalence of hypertension in both of these South 
African studies. In contrast, studies from Tanzania [7] 
and Uganda [7, 21] have reported a similar prevalence 
of hypertension in HIV-infected and HIV-uninfected 
participants, with those on ART in Tanzania having 
a higher BMI than those who were HIV-uninfected or 
HIV-infected and ART-naive.
Table 2 Comparison of anthropometric measures in females at baseline and follow-up (n = 103)
* Non-parametric paired t-test.
** McNemar Chi square test for paired data.
Baseline median (IQR), n = 103 Follow-up median (IQR) n = 94 P-value*
Height (m) 1.6 (1.5–1.6) 1.6 (1.5–1.6) 0.401
Weight (kg) 69.2 (61.4–81.1) 70.1 (59.7–78.8) 0.402
BMI 27.9 (24.8–31.8) 27.8 (23.9–31.6) 0.443
Sagittal height (cm) 21 (19–24) 20.6 (18.5–23.5) 0.640
Circumferences
 Waist (cm) 89.8 (81.3–96.8) 90.8 (82.5–100.0) 0.038
 Hip (cm) 103.0 (96.0–114.0) 100.0 (91.8–106.5) <0.001
 Waist-hip ratio 0.86 (0.81–0.92) 0.92 (0.85–0.98) <0.001
 Mid-upper arm (cm) 29.0 (27.0–32.0) 29.5 (26.8–32.5) 0.292
 Mid-thigh (cm) 58.0 (53.0–63.0) 55.0 (49.5–59.5) <0.001
Skinfold thickness
 Biceps (mm) 8.1 (5.8–10.5) 9.0 (6.4–12.6) 0.011
 Triceps (mm) 19.0 (12.6–25.2) 16.3 (11.3–22.5) 0.007
 Abdomen (mm) 25.1 (16.9–34.2) 32.2 (21.7–37.8] <0.001
 Thigh (mm) 32.8 (24.1–43.3) 24.3 (17.3–34.0) <0.001
 Sub-scapular (mm) 21.5 (13.4–28.8) 29.0 (18.8–34.2) <0.001
 Supra-iliac (mm) 16.1 (9.9–22.4) 20.5 (13.3–28.9] <0.001
 Calf (mm) 17.8 (12.3–24.4) 13.1 (7.0–19.2) <0.001
n (%) n (%) P-value**
Lipoatrophy
 Based on patient report 25 (24.5) 0 <0.001
 Based on thigh (≤28 mm) and triceps (≤14.5 mm) skinfold cut points 45 (43.7) 59 (64.1) 0.010
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Although the prevalence of new onset diabetes 
increased between baseline and follow-up in our study, 
this did not reach statistical significance, possibly due 
to the small sample size. Interestingly, the prevalence of 
new onset diabetes at follow-up, was twofold higher in 
our study than the prevalence of new onset diabetes in 
women of similar ages from the CRIBSA study [19]. The 
different methods used to assess dysglycaemia makes 
it difficult to compare studies from Africa. However, a 
study [22] that also used an OGTT to assess dysglycae-
mia found a similar prevalence of dysglycaemia, although 
the length of time on ART was longer in our study 
(81 months vs 48 weeks). The rise in insulin secretion in 
relation to insulin resistance, as expressed by the DIo, in 
the majority of the group at follow-up explains their lack 
of development of diabetes.
Although there was no increase in BMI at follow-up, 
the greater abdominal skinfold thickness and waist-hip 
ratio together with peripheral wasting suggests a marked 
difference in body composition with centralisation of 
body fat, in agreement with a number of other African 
studies [5, 13, 16, 23]. HIV-associated central fat accu-
mulation likely reflects the consequence of treating the 
HIV infection rather than a specific antiretroviral adverse 
drug reaction [17]. We found an increase in the percent-
age of participants with lipoatrophy when defined by 
thigh and triceps skinfold cut points [13]. However, when 
using patient report to diagnose lipoatrophy, no women 
had lipoatrophy, including the 25% who reported lipoat-
rophy at baseline. The discrepancy we found in the pro-
portion of women with lipoatrophy on anthropometry 
and patient report is likely due to the women having 
grown accustomed to their new body shape and illus-
trates the limitations of diagnosing lipodystrophy using 
a subjective measure. Lipoatrophy is an antiretroviral 
adverse drug reaction, strongly associated with the use 
of thymidine analogue nucleoside reverse transcriptase 
inhibitors (NRTI’s), stavudine and zidovudine [17]. In our 
study more than 30% of women were still on stavudine 
at follow-up and almost 20% were still taking zidovudine. 
The baseline prevalence of lipoatrophy we found is also 
similar to that of another South African study [16], which 
reported a 43% prevalence after 2 years of treatment, but 
they defined lipoatrophy only by subjective patient and 
healthcare worker reports.
Our study has some limitations. The lack of a HIV-
uninfected and ART-naïve control groups limits our abil-
ity to attribute the changes observed to the use of ART. 
The sample size was also relatively small, which limited 
our ability to assess whether the increased prevalence of 
Table 3 Comparison of  blood pressure, plasma glucose 
and  insulin concentrations and  markers of  insulin sen-
sitivity and  beta cell function at  baseline and  follow-up 
(n = 103)
* Non-parametric paired t-test.
a HOMA-IR = (fasting glucose × fasting insulin)/22.5.
b IGI = ΔInsulin0-30/ΔGlucose0-30.
c DIo [Oral disposition index] = (ΔInsulin0-30/ΔGlucose0-30) × (1/fasting insulin).
Baseline median (IQR) Follow-up median (IQR) P-value*
Blood Pressure
 Systolic 111 (101–121) 121 (112–133) <0.001
 Diastolic 72 (64–80) 80 (73–89) <0.001
Glucose
 Fasting 5.1 (4.7–5.4) 4.9 (4.7–5.3) 0.365
 30 min 6.6 (5.8–7.4) 6.8 (5.9–8.0) 0.040
 120 min 5.4 (4.9–6.3) 5.6 (4.7–6.8) 0.028
Insulin
 Fasting 5.6 (3.3–9.5) 7.9 (4.1–12.9) 0.009
 30 min 35.1 (19.2–66.7) 177.7 (163.4–192.5) <0.001
 120 min 24.0 (13.5–40.2) 23.7 (10.4–54.9) 0.993
Glycaemic parameters (without diabetics and outliers)
 HOMA-IRa 1.2 (0.7–2.2) 1.6 (0.9–2.7) 0.089
 IGIb 23.7 (11.9–33.1) 80.0 (54.0–137.4) <0.001
 DIo
c 3.5 (2.3–7.9) 11.9 (4.9–23.3) <0.001
Table 4 Comparison of blood pressure and glucose abnor-
malities in females at baseline and follow-up (n = 103)
* McNemar Chi square test for paired data.
a n = 94 at follow-up.
Baseline n (%) Follow-up n (%) P-value*
Hypertension 3 (3.9) 16 (15.5) <0.001
Glucose abnormalitiesa
 Diabetes 1 (1.0) 7 (7.5) 0.070
 Impaired glucose toler-
ance
6 (5.8) 9 (9.6) 0.344
 Impaired fasting Glucose 17 (16.5) 10 (10.5) 0.308
 Dysglycemia 22 (21.4) 19 (20) 1.00
Table 5 P-values* representing associations between  dia-
betes, hypertension, dysglycaemia and  lipoatrophy, 
and different antiretroviral drugs at follow-up
* McNemar Chi square test for paired data.
a Defined by thigh and tricep skinfold cut points.
Diabetes Hypertension Dysglycaemia Lipoatrophya
Stavudine 0.001 0.017 0.029 <0.001
Zidovudine 0.031 1 0.845 <0.001
Tenofovir 0.004 0.690 0.856 <0.001
Lopinavir 0.077 0.664 0.690 <0.001
Efavirenz 0.001 <0.001 <0.001 <0.001
Nevirapine <0.001 0.029 0.029 <0.001
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diabetes over time was significant. Despite these limita-
tions, ours is one of very few studies in Africa to use an 
OGTT to define dysglycemia and to follow women on 
ART for over 5 years.
Conclusion
In this study from Africa we observed that women who 
had been on ART for more than 5  years, developed 
increased blood pressure (systolic and diastolic). The 
prevalence of hypertension and diabetes also increased. 
The greatest changes observed were in body composi-
tion, with an increase in central fat and a decrease in 
subcutaneous fat. The prevalence of lipoatrophy, when 
defined by skinfold cut points, increased substantially. 
These findings have important implications for the man-
agement of HIV in Africa. The early identification and 
management of these cardiometabolic risks are crucial 




In our initial cross sectional study, undertaken in 2007–
2008 to examine the metabolic consequences of ART, a 
convenience sample of 345 HIV-infected black African 
women on first-line ART who were being followed up 
at ART clinics in Cape Town were selected. The recruit-
ment procedure is described elsewhere [5]. At that stage 
the first-line ART regimen consisted of stavudine, lami-
vudine or zidovudine and efavirenz or nevirapine, and 
the second-line regimen consisted of zidovudine with 
didanosine and lopinavir/ritonavir [24]. Subsequently, the 
first-line regimen was changed to tenofovir and efavirenz 
or nevirapine, and lamivudine replaced didanosine in the 
second-line regimen. NRTI drug substitutions for toxic-
ity or the convenience of a fixed dose combination are not 
considered switches to 2nd line ART. 103 of the initial 345 
participants could be traced approximately 5  years later 
and underwent repeated assessments. The remainder 
could not be traced using their home address or telephone 
number and were no longer attending the health facility 
from which they were recruited; defaulted, were pregnant 
or had died. The baseline characteristics did not differ 
between those we traced and those not traced.
Testing procedures
We used the same procedures to collect informa-
tion from participants at baseline and follow-up. 
Socio-demographic information was collected using 
an interviewer administered questionnaire. Clini-
cal records were obtained from health facilities and 
reviewed to obtain data on ART regimen, time on ART 
and, CD4 count. The Lipodystrophy Case Definition 
questionnaire [25] was used to collect self-reported 
information on fat gain or fat loss. Self-reported lipoat-
rophy was defined as in the HOPS study, as moderate 
or severe fat loss in 2 or more regions and self-reported 
lipohypertrophy defined as moderate or severe fat gain 
in two or more areas [26].
After an overnight fast, participants underwent a 75 g 
oral glucose tolerance test (OGTT). Venous blood sam-
ples were taken at 0, 30 and 120  min. The plasma was 
stored and analysed as previously described [5].
Anthropometric measurements: [weight, height, circum-
ferences (waist, hip, mid-upper arm, and mid-thigh), skinfold 
thickness (biceps, triceps, subscapular, abdomen, suprailiac, 
thigh and calf) and sagittal abdominal diameter (SAD)] were 
also done. Cut point based lipoatrophy was defined as hav-
ing a thigh skinfold thickness ≤28 mm or a triceps skinfold 
thickness of ≤14.5 mm [13]. Three BP measurements were 
taken at 2-min intervals using an Omron BP monitor with an 
appropriately sized cuff after the participant had been seated 
for 5 min. The average of the second and third BP measure-
ments was used in the analyses. Hypertension was defined as 
BP ≥140/90 mmHg or using antihypertensive agents. Diabe-
tes, IGT and IFG were defined using the American Diabetes 
Association criteria [27].
Ethical approval
The study proposal was submitted and approved by the 
Research Ethics Committee of the Faculty of Health Sci-
ences at the University of Cape Town. Written informed 
consent was obtained from all participants prior to par-
ticipation in the study, at baseline and again at follow-up.
Data analyses
Data analysis was carried out using the STATA/SE statis-
tical software package version 12.0 (StataCorp., College 
Station, TX, USA). Baseline data were collected between 
February 2007 and June 2009 and follow-up data between 
July 2011 and July 2013. Because the data were not nor-
mally distributed, continuous variables were described as 
medians and inter-quartile ranges (IQR), and were com-
pared using a non-parametric paired t test. Binary varia-
bles were described using numbers and percentages, and 
compared using the McNemar Chi square test for paired 
data.
Markers of beta cell function and insulin resistance 
were estimated in the participants who did not have dia-
betes at follow-up. Beta-cell function was estimated using 
(1) IGI, calculated as the ratio of the change in insulin to 
the change in glucose from 0 to 30  min (ΔInsulin0–30/
ΔGlucose0–30), and (2) DIo, calculated as a (ΔInsulin0-30/
ΔGlucose0–30)  ×  (1/fasting insulin). Insulin resistance 
was estimated using HOMA-IR, calculated as (fasting 
glucose × fasting insulin)/22.5.
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